176
Participants
Start Date
February 21, 2017
Primary Completion Date
April 23, 2019
Study Completion Date
October 25, 2023
Zilver® Paclitaxel-Eluting Peripheral Stent
Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating
Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating
Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
Auckland City Hospital, New Zealand, Auckland
Krankenhaud Bucholz, Buchholz
Klinikum Hochsauerland, Arnsberg
St. Josefskrankenhaus Heidelberg, Heidelberg
Marienhospital Stuttgart, Stuttgart
Uniklinikum Würzburg, Würzburg
SRH Klinikum Karlsbad- Langensteinbach GmbH, Karlsruhe
Universitäts Herzzentrum Freiburg - Bad Krozingen, Bad Krozingen
MEDINOS Kliniken des Landkreises Sonneberg GmbH, Sonneberg
Universitätsklinikum Jena, Jena
Universitatsklinikum Leipzig AoR, Leipzig
Cook Group Incorporated
INDUSTRY